CLINICAL RESULTS WITH THE USE OF DEANOL (DEANER®) IN SCHIZOPHRENIA
Abstract
Deanol was used in 100 institutionalized female schizophrenics. It was moderately effective in 25%, producing increased interest in milieu, work and recreation, and decreasing somatic delusional trends, depression, retardation, and mutism. Side actions were minimal, and all were controlled by dosage regulation.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).